ATE448782T1 - Pharmazeutische glutathionpräparate und methoden zu dern verabreichung - Google Patents

Pharmazeutische glutathionpräparate und methoden zu dern verabreichung

Info

Publication number
ATE448782T1
ATE448782T1 AT97952640T AT97952640T ATE448782T1 AT E448782 T1 ATE448782 T1 AT E448782T1 AT 97952640 T AT97952640 T AT 97952640T AT 97952640 T AT97952640 T AT 97952640T AT E448782 T1 ATE448782 T1 AT E448782T1
Authority
AT
Austria
Prior art keywords
glutathione
pharmaceutical
methods
administration
administration same
Prior art date
Application number
AT97952640T
Other languages
German (de)
English (en)
Inventor
Harry Demopoulos
Myron Seligman
Original Assignee
Antioxidant Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21874315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE448782(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antioxidant Pharmaceuticals Co filed Critical Antioxidant Pharmaceuticals Co
Application granted granted Critical
Publication of ATE448782T1 publication Critical patent/ATE448782T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
AT97952640T 1996-12-31 1997-12-31 Pharmazeutische glutathionpräparate und methoden zu dern verabreichung ATE448782T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3410196P 1996-12-31 1996-12-31
PCT/US1997/023879 WO1998029101A1 (en) 1996-12-31 1997-12-31 Pharmaceutical preparations of glutathione and methods of administration thereof

Publications (1)

Publication Number Publication Date
ATE448782T1 true ATE448782T1 (de) 2009-12-15

Family

ID=21874315

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97952640T ATE448782T1 (de) 1996-12-31 1997-12-31 Pharmazeutische glutathionpräparate und methoden zu dern verabreichung

Country Status (8)

Country Link
US (5) US6159500A (enExample)
EP (1) EP0957901B1 (enExample)
JP (1) JP2001507696A (enExample)
AT (1) ATE448782T1 (enExample)
AU (1) AU5620598A (enExample)
CA (2) CA2276183C (enExample)
DE (1) DE69739663D1 (enExample)
WO (1) WO1998029101A1 (enExample)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744593A (en) * 1996-02-15 1998-04-28 Heska Corporation Parasitic helminth larval thiol specific antioxidant proteins and nucleic acid molecules
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
ES2224415T3 (es) * 1998-01-06 2005-03-01 Cerus Corporation Metodos para inhibir desactivadores patogenos en materiales biologicos.
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
GB2367489B (en) * 2000-07-31 2005-02-09 Mars Inc Use of antioxidants
EP1257273A2 (en) * 1999-08-17 2002-11-20 University of Saskatchewan Technologies Inc. Improved treatment for acute physical insult to the central nervous system
US6642274B1 (en) 1999-09-09 2003-11-04 Gary W. Neal Methods and compositions for preventing and treating prostate disorders
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
ATE285236T1 (de) * 1999-09-21 2005-01-15 Enzo Leone Antivirale zusammensetzungen enthaltend yohimbin als therapeutischen wirkstoff
AU4085201A (en) * 2000-03-15 2001-09-24 Imperial College Innovations Limited Pharmaceutical composition
CA2404157A1 (en) * 2000-03-28 2001-10-04 Robert J. Delorenzo Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
GB0008689D0 (en) * 2000-04-07 2000-05-31 Nokia Networks Oy A method and system for processing signals
NZ521710A (en) * 2000-04-07 2004-06-25 Sang Geon Kim Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
EP1284653B1 (en) * 2000-05-09 2007-11-28 Nitromed, Inc. Infrared thermography and treatment of sexual dysfunctions
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
CA2424021A1 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
WO2003025831A2 (en) * 2001-09-14 2003-03-27 Roke Manor Research Limited Tag and tagging system
US6726809B2 (en) * 2001-09-26 2004-04-27 Albany International Corp. Industrial process fabric
WO2003032908A2 (en) * 2001-10-16 2003-04-24 University Of Kansas Novel prodrugs of n-h bond-containing compounds and methods of making thereof
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
AU2002357311A1 (en) * 2001-12-18 2003-06-30 Johns Hopkins University School Of Medicine Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
US20060099239A1 (en) * 2002-04-15 2006-05-11 Coleman Henry D Dietary supplement for promoting removal of heavy metals from the body
US20030194453A1 (en) * 2002-04-15 2003-10-16 Coleman Henry D. Dietary supplement
US20040213829A1 (en) * 2002-04-15 2004-10-28 Coleman Henry D. Dietary supplement
US20090011048A1 (en) * 2002-04-16 2009-01-08 Coleman Henry D Dietary Supplement For Promoting Removal Of Heavy Metals From The Body
WO2003092479A2 (en) * 2002-05-03 2003-11-13 Luc Montagnier Treatments and methods for the treatment, diagnosis and prophylaxis
US20100316700A1 (en) * 2002-11-07 2010-12-16 Guilford F Timothy Systemic administration of liposomal reduced glutathione for the decorporation of radioactive materials and non-radioactive mercury
US20070065497A1 (en) * 2005-09-20 2007-03-22 Guilford Frederick T Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US20040219600A1 (en) * 2002-12-13 2004-11-04 Williams Robert Wood Method for determining sensitivity to environmental toxins and susceptibility to parkinson's disease
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP4724111B2 (ja) * 2003-02-21 2011-07-13 メタボリックス インコーポレイティッド Ｐｈａブレンド
US7781539B2 (en) * 2003-02-21 2010-08-24 Metabolix Inc. PHA blends
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
JP2005104852A (ja) * 2003-09-29 2005-04-21 Kyowa Hakko Kogyo Co Ltd モービリウィルス感染症の予防または治療用組成物
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050143300A1 (en) * 2003-10-10 2005-06-30 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
DK1675578T3 (da) * 2003-10-15 2013-08-26 Probiodrug Ag Inhibitorer af glutaminyl- og glutamatcyclaser til behandling af de neurodegenerative sygdomme FBD og FDD
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
JP2007516294A (ja) * 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
ES2315737T3 (es) * 2003-12-30 2009-04-01 Metabolix, Inc. Agentes nucleantes.
US20050202521A1 (en) * 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
US8217084B2 (en) * 2004-05-24 2012-07-10 Allium Vitalis Incorporated Medicinal products incorporating bound organosulfur groups
JP5066448B2 (ja) 2004-09-03 2012-11-07 協和発酵バイオ株式会社 口内炎の予防または治療のための組成物および方法
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
ES2395555T3 (es) * 2004-11-07 2013-02-13 Your Energy Systems, LLC Formulación liposomal para la administración oral de glutatión (reducido)
WO2006066404A1 (en) * 2004-12-21 2006-06-29 Critical Care Connections, Inc. Therapeutic nutrient compositions or combinations and methods of their use
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
CN101150956B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
WO2006091610A2 (en) * 2005-02-23 2006-08-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
EP1888510A4 (en) 2005-05-27 2013-01-16 Univ North Carolina NITROGEN OXIDE-RELATED PARTICLES FOR NITROGEN OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
CA2615319A1 (en) * 2005-07-13 2007-01-18 Al Czap Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
WO2007033211A2 (en) * 2005-09-12 2007-03-22 The Board Of Regents Of The University Of Texas System Regulation of brain natriuretic peptide and catecholamines for the treatment of cardiovascular diseases
GB2430364A (en) * 2005-09-22 2007-03-28 Carl Ernest Alexander Soft agar bolus for oral drug delivery
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EA010926B1 (ru) * 2006-01-20 2008-12-30 Леонид Андреевич Кожемякин Средство для лечения туберкулеза глаз, способ его получения и применения
US20090047340A1 (en) * 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
EP2068893A2 (en) 2006-10-05 2009-06-17 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
WO2008112887A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
US20080318864A1 (en) * 2007-06-25 2008-12-25 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
GB0722923D0 (en) * 2007-11-22 2008-01-02 Uhi Millennium Inst Improved anti-platelet compositions
JP5406049B2 (ja) * 2008-02-05 2014-02-05 協和発酵バイオ株式会社 グルタチオンの保存安定性向上方法
JP5499714B2 (ja) * 2008-02-15 2014-05-21 味の素株式会社 腸管免疫賦活剤
EP2334279A4 (en) * 2008-10-16 2013-03-20 Novan Inc STAIN OXIDE RELEASING PARTICLES FOR MOUTH CARE APPLICATIONS
JP5208028B2 (ja) * 2009-03-16 2013-06-12 学校法人帝京大学 Ｅｄ評価方法
US8313456B2 (en) * 2009-06-30 2012-11-20 Palo Alto Research Center Incorporated Drug-transfer device, drug-delivery system incorporating the same, methods of fabricating the same, and methods of enabling administration of a drug
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
US20110086234A1 (en) * 2009-10-13 2011-04-14 Nathan Stasko Nitric oxide-releasing coatings
WO2011091807A1 (en) * 2010-01-31 2011-08-04 Abdelrahman Shata Mohammed Shata Anticoagulant and glutathione for treatment of cancer
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
EP2815760B1 (en) * 2012-02-15 2019-10-09 Kyowa Hakko Bio Co., Ltd. Agent for preventing or ameliorating vascular endothelial malfunction
US20130323324A1 (en) * 2012-06-01 2013-12-05 Franco Cavaleri Vanadium and vanadyl amino acid complexes
US20140179615A1 (en) * 2012-07-12 2014-06-26 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. Glutathione and Acetaminophen Composition and Preparation Method Thereof
US9475930B2 (en) 2012-08-17 2016-10-25 Metabolix, Inc. Biobased rubber modifiers for polymer blends
NZ706329A (en) * 2012-09-28 2018-06-29 Kyowa Hakko Bio Co Ltd Agent for enhancing immunity containing glutathione
US20140100283A1 (en) * 2012-10-05 2014-04-10 Atlantic Pro Nutrients, Inc. dba XYMOGEN Method to Increase Absorption and Bioavailability of Oral Glutathione
EP2990048B1 (en) 2013-01-21 2023-03-01 Kyowa Hakko Bio Co., Ltd. Nitric oxide concentration elevating agent
CN105531308B (zh) 2013-05-30 2021-08-10 Cj 第一制糖株式会社 回收物共混物
IL294448A (en) 2013-12-24 2022-09-01 Univ Virginia Commonwealth Uses of oxidized cholesterol sulfates
WO2015120458A1 (en) 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury
CA2961380A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
AU2015330807A1 (en) * 2014-10-09 2017-04-13 Albert Crum Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
WO2017091737A1 (en) * 2015-11-25 2017-06-01 Molecular Defenses Corporation Pharmaceutical formulations
US10702590B2 (en) * 2016-04-12 2020-07-07 Script Essentials, Llc Compositions and methods for treating thyroid disease
WO2018007878A1 (en) * 2016-07-05 2018-01-11 CanTrust LifeScience Corp. Methods of treating and preventing gout and lead nephropathy
CN110198728A (zh) 2016-11-17 2019-09-03 莱诺翁股份有限公司 用谷胱甘肽组合物治疗呼吸道疾病和感染
WO2019099946A1 (en) 2017-11-17 2019-05-23 Renovion, Inc. Stable ascorbic acid compositions and methods of using the same
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
EP3733197A1 (en) * 2019-04-30 2020-11-04 Stephen N. Pitcher Anaerobic antioxidant composition
JP2022074429A (ja) * 2020-11-04 2022-05-18 三菱商事ライフサイエンス株式会社 グルタチオン機能促進剤及びその方法
WO2022168169A1 (ja) * 2021-02-02 2022-08-11 学校法人日本医科大学 抗ウイルス剤
IL313997A (en) 2022-01-04 2024-08-01 Renovion Inc Aqueous solution including glutathione salt
IT202200007238A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
IT202200007229A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
WO2023199241A1 (en) * 2022-04-12 2023-10-19 URIACH ITALY S.r.l. Composition comprising lipoic acid, vitamin d and glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof
EP4507687A1 (en) * 2022-04-12 2025-02-19 URIACH ITALY S.r.l. Composition comprising n-acetylcysteine, vitamin d and preferably glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof
IT202200007232A1 (it) * 2022-04-12 2023-10-12 Uriach Italy S R L Composizione comprendente acido lipoico, vitamina d e glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
KR102602347B1 (ko) * 2022-05-09 2023-11-15 천현수 위장내 발암성 엔-니트로사민 생성 억제 및 장내 산화질소 생성 촉진용 천연 조성물 및 이의 용도

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1444024A (en) * 1973-07-20 1976-07-28 Passwaterr A Food and feed supplents
FR2461002A1 (fr) 1979-07-13 1981-01-30 Inst Nat Sante Rech Med Procede pour stimuler la croissance des cellules d'epiderme humain et produits faisant application dudit procede
US4381307A (en) 1980-10-31 1983-04-26 Merck & Co., Inc. Soft tertiary amine esters of bio-affecting carboxylic acids
US4477435A (en) 1981-05-19 1984-10-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for regenerating corneal epithelium
US4414212A (en) * 1981-12-10 1983-11-08 Graham J. Naylor Method of treatment of pre-menstrual syndrome
US4454125A (en) 1982-04-22 1984-06-12 Demopoulos Harry B Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof
US4770877A (en) 1982-08-03 1988-09-13 Boston Biomedical Research Institute Isolation of a high molecular weight aortic endothelial cell growth inhibitor
US4534967A (en) 1982-08-03 1985-08-13 Boston Biomedical Research Institute Cell proliferation inhibitor and method of preparation
FI864293A7 (fi) 1985-02-26 1986-10-23 Univ Johns Hopkins Uusverisuonituksen inhibiittoreita ja niiden valmistus- ja käyttömene telmiä.
JPS62169723A (ja) * 1986-01-22 1987-07-25 Teisan Seiyaku Kk 徐放化製剤
US6030950A (en) * 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5061729A (en) 1988-06-08 1991-10-29 Biogal Gyogyszergyar Pharmaceutical composition and process for preparing the same
IT1231012B (it) 1989-07-27 1991-11-08 Zambon Spa Composizione farmaceutica per uso orale contenente nac.
JP2919870B2 (ja) * 1989-09-29 1999-07-19 千寿製薬株式会社 肝障害抑制剤
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
ES2176179T3 (es) 1991-02-01 2002-12-01 Suntory Ltd Composiciones antibacterianas orales y metodo para la mejora de la absorcion gastrointestinal de los antibioticos de penemo o carbapemo.
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
EP0746202A4 (en) * 1992-01-06 1997-06-25 Health Maintenance Programs COMPOSITION CONTAINING A PHARMACEUTICALLY ACTIVE ANTI-OXIDANT AND METHOD FOR USE IN THE PREVENTION AND TREATMENT OF RESTENOSIS AFTER ANGIOPLASTY
US5204114A (en) * 1992-03-30 1993-04-20 Health Maintenance Programs, Inc. Methods of manufacturing high dosage glutathione the tablets and capsules produced thereby
AU661379B2 (en) * 1992-04-23 1995-07-20 Transcend Therapeutics, Inc Method of reducing or preventing toxicity associated with antiretroviral therapy
US6319687B1 (en) 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US5840686A (en) 1992-09-24 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
WO1995003063A1 (en) 1993-07-22 1995-02-02 Esseti S.A.S. Laboratorio Chimico Farmaco Biologico Di A. Ievoli & C. Oral pharmaceutical compositions comprising reduced glutathion
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5985926A (en) 1993-11-01 1999-11-16 Cell Therapeutics, Inc. Method for inhibiting intracellular viral replication
US5679541A (en) 1994-02-14 1997-10-21 California Institute Of Technology Programmed cell death antagonist protein
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6015665A (en) 1995-02-13 2000-01-18 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US5674907A (en) 1995-03-24 1997-10-07 Children's Hospital Medical Center Mercapto derivatives as inhibitors of nitric oxide synthase
US5929063A (en) 1995-03-24 1999-07-27 Children's Hospital Medical Center Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
US5681711A (en) 1995-03-27 1997-10-28 University Of California-Los Angeles Method for promoting apoptosis in mammalian neual cells
US5804376A (en) 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US5985331A (en) * 1995-05-19 1999-11-16 New York Blood Center, Inc. Methods of use of phthalocyanines to inactivate blood borne parasites
US5932425A (en) 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
US6011067A (en) 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases

Also Published As

Publication number Publication date
US6159500A (en) 2000-12-12
EP0957901A1 (en) 1999-11-24
US6204248B1 (en) 2001-03-20
EP0957901A4 (en) 2006-04-12
DE69739663D1 (de) 2009-12-31
EP0957901B1 (en) 2009-11-18
JP2001507696A (ja) 2001-06-12
US6423687B1 (en) 2002-07-23
US6586404B1 (en) 2003-07-01
WO1998029101A1 (en) 1998-07-09
CA2276183C (en) 2009-06-09
US6350467B1 (en) 2002-02-26
AU5620598A (en) 1998-07-31
CA2650204A1 (en) 1998-07-09
CA2276183A1 (en) 1998-07-09

Similar Documents

Publication Publication Date Title
ATE448782T1 (de) Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
ES2157975T3 (es) Soluciones farmaceuticas con solubilidad mejorada.
IE871584L (en) Sustained release capsule.
DE3686936D1 (de) Am zielorgan wirkendes enterales abgabesystem.
PL341055A1 (en) Novel form of a drug for oral administration of active compounds being unstable in acid environments
HUP9903734A2 (hu) Szabályozott felszabadulású, orális gyógyszerkészítmények és eljárás ezek előállítására
FI944035A0 (fi) Tramadolisuolaa sisältävä lääkeaine, jolla on viivästynyt vaikuttavan aineen vapautuminen
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
CA2279522A1 (en) Biocompatible compounds for pharmaceutical drug delivery systems
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE3783430D1 (de) Bedingte dosierungsvorrichtung.
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
MY132911A (en) Clear, injectable solution of an anesthetic compound
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
ATE292453T1 (de) Antivirale arznei
DK0652744T3 (da) Farmaceutiske midler til afgivelse af peptider gennem slimhinden
ATE484295T1 (de) Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
ITMI921413A0 (it) Preparazioni farmaceutiche stabili di nicorandil
DE50003454D1 (de) Proteinenthaltende pharmazeutische zubereitung
NO892764L (no) Medikamentell administreringsform for droevtyggere.
EP0271151A3 (en) Azumolene dosage form
DK0615444T3 (da) Peroral indgivelsesform til peptidlægemidler, især insulin
PL325242A1 (en) Method of obtaining solid drug administration forms for very low dosage drugs
ITMI913335A1 (it) Sistema farmaceutico per la somministrazione a rilascio controllato di didropiridine terapeuticamente attive e metodo di preparazione

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties